Cost effectiveness of hepatitis c-related interventions targeting substance users and other high-risk groups: A systematic review

PharmacoEconomics

Volumn 30, Issue 11, 2012, Pages 1015-1034

  John Baptiste, Ava ^a,b,c   Yeung, Man Wah ^a   Leung, Victoria ^a   Van Der Velde, Gabrielle ^a,d   Krahn, Murray ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c WOMEN S COLLEGE HOSPITAL   (Canada)

^d INSTITUTE FOR WORK AND HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ANTIVIRAL THERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; HEPATITIS C; HIGH RISK POPULATION; HUMAN; INFECTION PREVENTION; LIVER BIOPSY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCREENING TEST; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; VIRUS DIAGNOSIS;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; HEPATITIS C; HUMANS; INTERFERONS; MASS SCREENING; POLYETHYLENE GLYCOLS; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84867283025     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/11597660-000000000-00000     Document Type: Review

References (63)

1. Global surveillance and control of hepatitis C: report of a WHO consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999 Jan; 6 (1): 35-47
2. Bruandet A, Lucidarme D, Decoster A, et al. Incidence and risk factors of HCV infection in a cohort of intravenous drug users in the North and East of France [in French]. Rev Epidemiol Sante Publique 2006; 54 (Suppl. 1): 1S15-22
3. Crofts N, Jolley D, Kaldor J, et al. Epidemiology of hepatitis C virus infection among injecting drug users in Australia. J Epidemiol Comm Health 1997 Dec; 51 (6): 692-7
4. Judd A, Hickman M, Jones S, et al. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ 2005; 330 (7481): 24-5
5. Miller CL, Spittal PM, Frankish JC, et al. HIV and hepatitis C outbreaks among high-risk youth in Vancouver demands a public health response. Can J Public Health 2005 Mar-Apr; 96 (2): 107-8
6. Wong JB. Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies. Pharmacoeconomics 2006; 24 (7): 661-72
7. Jacobson IM, Brown Jr RS, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007 Oct; 46 (4): 971-81
8. Dienstag JL, McHutchison JG. American gastroenterological association technical review on the management of hepatitis C. Gastroenterology 2006; 130 (1): 231-64
9. John-Baptiste A, Varenbut M, Lingley M, et al. Treatment of hepatitis C infection for current or former substance abusers in a community setting. J Viral Hepat 2009 Aug; 16 (8): 557-67
10. Sylvestre DL, Clements BJ. Adherence to hepatitis C treatment in recovering heroin users maintained on methadone. Eur J Gastroenterol Hepatol 2007 Sep; 19 (9): 741-7
11. Canadian Agency for Drugs and Technologies in Health. Grey matters: a practical search tool for evidence-based medicine [online]. Available from URL: http://www.cadth.ca/en/resources/grey-matters [Accessed 2011 Mar 25]
12. Drummond M, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd rev. ed. New York: Oxford University Press Inc., 1997
13. The World Bank. Global purchasing power parities and real expenditures: 2005 international comparison program. Washington, DC: International Bank for Reconstruction and Development/The World Bank, 2008 [online]. Available from URL: http://siteresources.worldbank.org/IC-PINT/Resources/icp-final.pdf [Accessed 2011 Sep 27]
14. The World Bank. International comparison program [online]. Available from URL: http://data.worldbank.org/data-catalog [Accessed 2011 Mar 25]
15. U.S. Bureau of Labor Statistics. Consumer price index for all urban consumers (CPI-U) 1982-84=100 (Unadjusted)-CUUR0000SA0 [online]. Available from URL: http://146.142.4.24/cgi-bin/surveymost?bls [Accessed 2011 Mar 25]
16. Campos NG, Salomon JA, Servoss JC, et al. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med 2007; 120 (3): 272-9
17. Kuehne FC, Bethe U, Freedberg K, et al. Treatment for hepatitis C virus in human immunodeficiency virusinfected patients: clinical benefits and cost-effectiveness. Arch Intern Med 2002 Dec; 162 (22): 2545-56
18. Sutton AJ, Edmunds WJ, Gill ON. Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison. BMC Public Health 2006 Jun 27; 6: 170
19. Shiroiwa T, Sung Y-K, Fukuda T, et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ 2010; 19 (4): 422-37
20. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992 Feb 15; 146 (4): 473-81
21. McCabe C, Dixon S. Testing the validity of cost-effectiveness models. Pharmacoeconomics 2000; 17 (5): 501-13
22. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48 (2): 418-31
23. Yi Q, Wang PP, Krahn M. Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection. J Viral Hepat 2004 Mar; 11 (2): 166-74
24. Amin J, Law MG, Bartlett M, et al. Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006 Sep 9; 368 (9539): 938-45
25. Krajden M, Kuo M, Zagorski B, et al. Health care costs associated with hepatitis C: a longitudinal cohort study. Can J Gastroenterol 2010 Dec; 24 (12): 717-26
26. Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999 Dec 15; 18 (23): 3263-82
27. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996 Aug 3; 313 (7052): 275-83
28. Philips Z, Bojke L, Sculpher M, et al. Good practice guide-lines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006; 24 (4): 355-71
29. Neumann PJ, Stone PW, Chapman RH, et al. The quality of reporting in published cost-utility analyses, 1976-1997. Ann Intern Med 2000; 132 (12): 964-72
30. World Health Organization. WHO Statistical Information System (WHOSIS) [online]. Available from URL: http://www.who.int/whosis/en/ [Accessed 2012 Aug 13]
31. Wong J, Sylvestre DL, Siebert U. Cost-effectiveness of treatment of hepatitis C in injecting drug users. In: Jager J, Limburg W, Kretzschmar M, et al., editors. Hepatitis C and injecting drug use: impact, costs and policy options [European Monitoring Centre for Drugs and Drug Addiction scientific monograph series no. 7]. Luxembourg: Office for Official Publications of the European Communities, 2004: 219-41 [online]. Available from URL: http://www.emcdda.europa.eu/html.cfm/index31213EN.html [Accessed 2012 Aug 13]
32. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. CMAJ 2008 Nov 18; 179 (11): 1143-51
33. Castelnuovo E, Thompson-Coon J, Pitt M, et al. The cost-effectiveness of testing for hepatitis C in former injecting drug users. Health Technol Assess 2006; 10 (32): iii-79
34. Hornberger J, Torriani FJ, Dieterich DT, et al. Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol 2006 Aug; 36 (4): 283-91
35. Josset V, Torre JP, Tavolacci MP, et al. Efficiency of hepatitis C virus screening strategies in general practice. Gastroenterol Clin Biol 2004 Apr; 28 (4): 351-7
36. Lapane KL, Jakiche AF, Sugano D, et al. Hepatitis C infection risk analysis: who should be screened? Comparison of multiple screening strategies based on the National Hepatitis Surveillance Program. Am J Gastroenterol 1998 Apr; 93 (4): 591-6
37. Loubiere S, Rotily M, Moatti JP. Prevention could be less cost-effective than cure: the case of hepatitis C screening policies in France. Int J Technol Assess Health Care 2003; 19 (4): 632-45
38. Pollack HA. Cost-effectiveness of harm reduction in preventing hepatitis C among injection drug users. Med Decis Making 2001 Sep-Oct; 21 (5): 357-67
39. Ravasio R. Costo efficacia di peginterferone α-2a + ribavirina verus peginterferone α-2b + ribavirina nel trattamento dell'epatite cronica di tipo C in pazienti HIV coinfetti. Pharmacoeconomics - Italian Research Articles 2008; 10 (1): 37-47
40. Schackman BR, Oneda K, Goldie SJ. The cost-effectiveness of elective caesarean delivery to prevent hepatitis C transmission in HIV-coinfected women. AIDS 2004; 18 (13): 1827-34
41. Sheerin IG, Green FT, Sellman JD. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? Drug Alcohol Rev 2004 Oct; 23 (3): 261-72
42. Stein K, Dalziel K, Walker A, et al. Screening for hepatitis C in genito-urinary medicine clinics: a cost utility analysis. J Hepatol 2003 Nov; 39 (5): 814-25
43. Stein K, Dalziel K, Walker A, et al. Screening for hepatitis C in injecting drug users: a cost utility analysis. J Public Health 2004 Mar; 26 (1): 61-71
44. Sterling RK, Brown Jr RS, Hofmann CM, et al. The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV. Am J Gastroenterol 2005 Feb; 100 (2): 313-21
45. Sutton AJ, Edmunds WJ, Sweeting MJ, et al. The cost-effectiveness of screening and treatment for hepatitis C in prisons in England and Wales: a cost-utility analysis. J Viral Hepat 2008 Nov; 15 (11): 797-808
46. Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison population is cost-saving. Hepatology 2008 Nov; 48 (5): 1387-95
47. Thompson Coon J, Castelnuovo E, Pitt M, et al. Case finding for hepatitis C in primary care: a cost utility analysis. Fam Pract 2006 Aug; 23 (4): 393-406
48. Tramarin A, Gennaro N, Compostella FA, et al. HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations. Curr Pharm Des 2008; 14 (17): 1655-60
49. Adam T, Koopmanschap MA, Evans DB. Cost-effectiveness analysis: can we reduce variability in costing methods? Int J Technol Assess Health Care 2003; 19 (2): 407-20
50. Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection. Eur J Public Health 2009 Jun; 19 (3): 245-53
51. Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat 2010 Jan; 17 (1): 34-50
52. Fleming CA, Tumilty S, Murray JE, et al. Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: need for team care. Clin Infect Dis 2005 Apr 15; 40 Suppl. 5: S349-54
53. Grebely J, Genoway KA, Raffa JD, et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 2008; 93 (1-2): 141-7
54. Fleming CA, Craven DE, Thornton D, et al. Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. Clin Infect Dis 2003; 36 (1): 97-100
55. Wilkinson M, Crawford V, Tippet A, et al. Community-based treatment for chronic hepatitis C in drug users: high rates of compliance with therapy despite ongoing drug use. Aliment Pharmacol Ther 2009 Jan; 29 (1): 29-37
56. Grebely J, Genoway K, Khara M, et al. Treatment uptake and outcomes among current and former injection drug users receiving directly observed therapy within a multi-disciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18 (5): 437-43
57. Costenbader EC, Zule WA, Coomes CM. The impact of illicit drug use and harmful drinking on quality of life among injection drug users at high risk for hepatitis C infection. Drug Alcohol Depend 2007; 89 (2-3): 251-8
58. Dalgard O, Egeland A, Skaug K, et al. Health-related quality of life in active injecting drug users with and without chronic hepatitis C virus infection. Hepatology 2004 Jan; 39 (1): 74-80
59. Bate JP, Colman AJ, Frost PJ, et al. High prevalence of late relapse and reinfection in prisoners treated for chronic hepatitis C. J Gastroenterol Hepatol 2010; 25 (7): 1276-80
60. Grebely J, Conway B, Raffa JD, et al. Hepatitis C virus reinfection in injection drug users. Hepatology 2006; 44 (5): 1139-45
61. Grebely J, Knight E, Ngai T, et al. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol 2010; 25 (7): 1281-4
62. Currie SL, Ryan JC, Tracy D, et al. A prospective study to examine persistent HCV reinfection in injection drug users who have previously cleared the virus. Drug Alcohol Depend 2008; 93 (1-2): 148-54
63. Rodger AJ, Jolley D, Thompson SC, et al. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999 Nov; 30 (5): 1299-301